DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Olmutinib is an investigational drug.
There have been 6 clinical trials for Olmutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Konkuk University Medical Center, and Boehringer Ingelheim.
There are four US patents protecting this investigational drug and eighty-one international patents.
Recent Clinical Trials for Olmutinib
|Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA||Hanmi Pharmaceutical Company Limited||Phase 2|
|Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA||Konkuk University Medical Center||Phase 2|
|Olmutinib (BI 1482694) ADME Study||Boehringer Ingelheim||Phase 1|
Top disease conditions for Olmutinib
Top clinical trial sponsors for Olmutinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Olmutinib||Start Trial||Method for preparing thienopyrimidine compound and intermediates used therein||HANMI PHARM. CO., LTD. (Hwaseong-si, KR)||Start Trial|
|Olmutinib||Start Trial||Fused pyrimidine derivatives for inhibition of tyrosine kinase activity||Hanmi Science Co., Ltd (Hwaseong-si, KR)||Start Trial|
|Olmutinib||Start Trial||Fused pyrimidine derivatives for inhibition of tyrosine kinase activity||Hanmi Science Co., Ltd. (Hwaseong-Si, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Olmutinib||European Patent Office||3224257||2034-12-30||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|